Guardant Health
Korean AI Pathology Startup Lunit Nabs $26M Investment from Guardant Health; Plans Collaboration
Having closed a Series C funding round, the firm is completing clinical validation, and will collaborate with Guardant to develop new precision oncology products.
The firm announced the new test, Guardant360 Response, alongside its launch of its Guardant360 TissueNext tumor tissue genomic profiling product.
May Lag for Many Dx Firms' Stock Prices as 360Dx Index Drops 4 Percent
Of the 30 companies in the index, 18 firms saw their stock prices decrease, while 12 firms' share prices increased.Â
FDA Approves Amgen's Lumakras for NSCLC Alongside Companion Tests From Guardant Health, Qiagen
The approval makes Lumakras the first inhibitor of KRAS, once considered "undruggable," to reach the market for KRAS-mutated NSCLC.
Guardant Health Sues Natera for False Advertising, 'Misleading' Oncologists About MRD Tests
Guardant has asked the court to recover damages and to prevent Natera from further disseminating "deceptive" advertising regarding their competing assays.
May 6, 2021
Guardant Health Q1 Revenues up 17 Percent
Feb 24, 2021
Guardant Health Q4 Revenues Up 25 Percent
Feb 5, 2021
Nov 17, 2020
Guardant Health Prices $1B Senior Notes Offering
Nov 5, 2020